Understanding Bronchiectasis: A Review of Inflammation Patterns and Treatment Options

Bronchiectasis is a chronic inflammatory airway disease characterized by impaired mucociliary clearance, persistent infection, and progressive structural lung damage. While inflammation is central to disease activity and progression, targeted anti-inflammatory treatments have been limited. Researchers from the Mayo Clinic have conducted a review to explore key inflammation patterns, biomarkers, and available treatments across the spectrum of inflammation in bronchiectasis. The review simplifies complex concepts, underscores key aspects of diagnostic evaluation, and discusses both conventional and emerging treatments for bronchiectasis, providing practical insights for improved personalized patient care.

Key Takeaways:

• Bronchiectasis is a chronic inflammatory airway disease characterized by a self-perpetuating vortex of impaired mucociliary clearance, persistent infection, and progressive structural lung damage.
• Neutrophilic inflammation remains the hallmark of bronchiectasis, with promising reversible dipeptidyl peptidase-1 inhibitors reducing the activation of neutrophil serine proteases during neutrophil maturation.
• Eosinophilic inflammation has also gained attention, with evidence indicating that patients with this endotype may benefit from glucocorticoids and biologic therapies targeting type 2 inflammation.
• Impaired epithelial function and mucociliary abnormalities, immune dysregulation, and airway inflammation triggered by infections, environmental irritants, and autoimmune conditions are additional inflammatory mechanisms discussed in the review.
• The review emphasizes the importance of understanding the different types of inflammation involved and their significant overlap for effective management of bronchiectasis.

Statistics:

• 244: The volume number of the publication where the research was published (Respiratory Medicine).
• 32: The address number of the publisher's office (W B Saunders Co Ltd).
• 7BY: The postal code of the publisher's office (London, England, NW1 7BY).
• 2025: The year of publication of the research.
• 3303: The page number of the news report (Respiratory Therapeutics Week).

Sources:

• Bronchiectasis: a Clinical Review of Inflammation. Respiratory Medicine, 2025;244.
• W B Saunders Co Ltd, 32 Jamestown Rd, London NW1 7BY, England. (Elsevier - www.elsevier.com; Respiratory Medicine - www.journals.elsevier.com/respiratory-medicine/)
• Amjad N. Kanj, Mayo Clinic, Dept. of Medicine, Division of Pulmonary & Critical Care Medicine, Rochester, MN, United States.
• George Doumat and Timothy R. Aksamit, Additional authors of the research.